A Multicenter, Open-label, Non-randomized, Dose-escalation, Therapeutic Exploratory Trial to Evaluate the Safety and Efficacy of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 23 May 2016
At a glance
- Drugs OPB 31121 (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 25 Mar 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 15 May 2013 Planned End Date changed from 1 Feb 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov record.
- 04 Aug 2011 New trial record